Estimate the maximum tolerated dose and/or recommended phase two dose and efficacy of FGF401 on patients with solid malignancies
A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
The purpose of this study is to find a recommended schedule and dose range for LY2875358 when given with ramucirumab that may be safely given to participants with cancer. In Part A of this study, escalating doses of LY2875358 will be given in combination with a fixed dose of ramucirumab… Read more »
Find Clinical Trials
To find clinical trials that focus on targeted therapies, use the pulldown menus below or enter a term in the search box.
Request a Consultation
To schedule a consultation with an oncologist at Dana-Farber/Brigham and Women's Cancer Center, please call one of our experienced appointment coordinators.
